Mesoblast (MESO) announced the United States FDA has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy, Revascor, Regenerative Medicine Advanced Therapy designation following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome, a potentially life threatening congenital heart condition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO: